SCHEMBL30217575

SCHEMBL30217575

Cc1ccc2c(N3CCN(C(=O)OC(C)(C)C)CC3)ccc(C(=O)O)c2n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CKS1B P61024 2/20 0.44
SKP1 P63208 2/20 0.44
SKP2 Q13309 2/20 0.44
MAP4K4 O95819 1/20 0.43
GPR119 Q8TDV5 2/20 0.42
BACE1 P56817 1/20 0.42
SLC2A1 P11166 1/20 0.42
GBA1 P04062 2/20 0.42
PTPN11 Q06124 1/20 0.42
MAPT P10636 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
MEN1 O00255 1/20 0.41
TSHR P16473 1/20 0.41
KMT2A Q03164 1/20 0.41
ALDH1A1 P00352 1/20 0.41
LMNA P02545 1/20 0.41
ACHE P22303 1/20 0.41
SMPD3 Q9NY59 1/20 0.41
KIT P10721 1/20 0.40
POLB P06746 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25096858 1.00 CKS1B (0.44) CKS1BSKP1SKP2MAP4K4GPR119
SCHEMBL25096832 0.89 BACE1 (0.43) CKS1BSKP1SKP2MAP4K4GPR119
SCHEMBL30217692 0.89 BACE1 (0.43) CKS1BSKP1SKP2MAP4K4GPR119
SCHEMBL30217766 0.87 CKS1B (0.43) CKS1BSKP1SKP2MAP4K4GPR119
SCHEMBL25096668 0.87 CKS1B (0.43) CKS1BSKP1SKP2MAP4K4GPR119
SCHEMBL4185271 0.85 MEN1 (0.44) CKS1BSKP1SKP2MAP4K4GPR119
SCHEMBL2878919 0.85 MAP4K4 (0.43) CKS1BSKP1SKP2MAP4K4GPR119
SCHEMBL30161994 0.83 SMARCA2 (0.44) CKS1BSKP1SKP2MAP4K4GPR119
SCHEMBL25095904 0.82 POLB (0.42) CKS1BSKP1SKP2MAP4K4GPR119
SCHEMBL30217642 0.82 POLB (0.42) CKS1BSKP1SKP2MAP4K4GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240409536-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING REMIX THERAPEUTICS INC. 2024-12-12 US disclosed
EP-4395891-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING Remix Therapeutics Inc. (US) 2024-07-10 EP disclosed
CN-118234724-A Compounds and methods for modulating splicing 雷密克斯医疗公司 2024-06-21 CN disclosed
WO-2023034811-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING REMIX THERAPEUTICS INC. (US) 2023-03-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240409536-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING RBM17, SNRPA, SNRPA1 CKS1B 1184/4885SKP1 4040/4885SKP2 3596/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.